Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Safety and Efficacy of Standard of Care (SOC) Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM), a Single Center Experience

Blood (2024) 144 (Supplement 1): 7832.

https://doi.org/10.1182/blood-2024-204276

Published: 2024

Journal Articles

Activity and Safety of Venetoclax (VEN)-Based Treatment in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (R/R MM)

Filip Ionescu, Shrinjaya B Thapa, Parth C Patel, Dimitrios Drekolias, Ariosto Siqueira Silva, Praneeth R Sudalagunta, Phaedra Agius, Brandon Blue, Doris K. Hansen, Omar Castaneda, Hien Liu, Jose L. Ochoa-Bayona, Ciara Louise Freeman, Frederick Locke, Taiga Nishihori, Melissa Alsina, Kenneth H. Shain, Rachid Baz, Ariel Grajales-Cruz

Blood (2024) 144 (Supplement 1): 4740.

https://doi.org/10.1182/blood-2024-210069

Published: 2024

Journal Articles

Clinical Characteristics and Outcomes of Patients with MYD88 Positive Waldenström Macroglobulinemia: A Single Center Retrospective Analysis

Shrinjaya B Thapa, David Kaldas, Jose Laborde, Shrikar Modukuri, Filip Ionescu, Brandon Blue, Julio C. Chavez, Melissa Alsina, Celeste M. Bello, Javier Pinilla-Ibarz, Kenneth H. Shain, Rachid C. Baz, Ariel Grajales-Cruz

Blood (2024) 144 (Supplement 1): 3021.

https://doi.org/10.1182/blood-2024-208701

Published: 2024

Journal Articles

Effect of Talquetamab on Responses in Patients with Relapsed and Refractory Multiple Myeloma with Prior Exposure to T-Cell Redirecting Therapies

Blood (2024) 144 (Supplement 1): 5168.

https://doi.org/10.1182/blood-2024-211739

Published: 2024

Journal Articles

Single Center Real World Experience of Talquetamab in Patients with Relapsed and Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 3784.

https://doi.org/10.1182/blood-2024-204232

Published: 2024

Journal Articles

Cladribine and Cyclophosphamide Lymphodepletion Prior to Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 4884.

https://doi.org/10.1182/blood-2023-187078

Published: 2023

Journal Articles

Cladribine and Cyclophosphamide Lymphodepletion Prior to Brexucabtagene Autoleucel in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia and Mantle Cell Lymphoma

Filip Ionescu, Rawan Faramand, Hanna Bailey, Christina A Bachmeier, Elizabeth DiMaggio, Turab Mohammed, Leidy Lismeris Isenalumhe, Frederick L. Locke, Michael D. Jain, Bijal D. Shah

Blood (2023) 142 (Supplement 1): 6904.

https://doi.org/10.1182/blood-2023-190973

Published: 2023

Journal Articles

Alternative Lymphodepletion Strategies Lead to Similar Response Rates and Toxicities in Standard-of-Care BCMA-Directed CAR-T Therapy in Relapsed Refractory Multiple Myeloma

Blood (2023) 142 (Supplement 1): 3499.

https://doi.org/10.1182/blood-2023-187565

Published: 2023

Journal Articles

Poor Hematopoietic Reserve at the Time of CD19 CAR T-Cell Infusion Is Associated with Long Term B-Cell Aplasia

Blood (2023) 142 (Supplement 1): 3512.

https://doi.org/10.1182/blood-2023-185097

Published: 2023

Journal Articles

Second-Line Chimeric Antigen Receptor T Cell Therapy (CAR-T) As Standard of Care for Relapsed-Refractory Large B-Cell Lymphoma (LBCL)

Saurabh Dahiya, Jay Y. Spiegel, Dasom Lee, Turab Mohammed, Forat Lutfi, Anmol Goyal, Caroline Hana, Julio C Chavez, Filip Ionescu, Matthew J. Frank, Sushma Bharadwaj, Jose Sandoval-Sus, Amer M. Beitinjaneh, Lazaros J. Lekakis, Joseph P McGuirk, Frederick L. Locke, David B. Miklos, Michael D. Jain

Blood (2023) 142 (Supplement 1): 4876.

https://doi.org/10.1182/blood-2023-188918

Published: 2023

Journal Articles

Fludarabine Lymphodepletion Exposure Is Associated with Idecabtagene Vicleucel Toxicity in Relapsed and Refractory Multiple Myeloma Patients: Real-World Experience from the US Myeloma Immunotherapy Consortium

Blood (2023) 142 (Supplement 1): 4880.

https://doi.org/10.1182/blood-2023-187440

Published: 2023

Journal Articles

Outcomes of Acute Myeloid Leukemia Relapsed Post-Allogeneic Hematopoietic Stem Cell Transplant Treated with Hypomethylating Agents and Venetoclax Combination: A Single Center Experience

Filip Ionescu, David A. Sallman, Kendra Sweet, Rami S. Komrokji, Onyee Chan, Andrew Kuykendall, Eric Padron, Rawan Faramand, Nelli Bejanyan, Farhad Khimani, Hany Elmariah, Joseph Pidala, Asmita Mishra, Lia Perez, Taiga Nishihori, Jeffrey E. Lancet

Blood (2022) 140 (Supplement 1): 1288–1290.

https://doi.org/10.1182/blood-2022-165661

Published: 2022

Journal Articles

Outpatient Treatment with Anti-Sars-Cov-2 Monoclonal Antibodies and Remdesivir for COVID19 Infections Demonstrates Encouraging Outcomes in Hematopoietic Stem Cell Transplant Recipients: A Single-Center Experience

Blood (2022) 140 (Supplement 1): 10488–10490.

https://doi.org/10.1182/blood-2022-170337

Published: 2022

Journal Articles

Efficacy of Partial Splenic Embolization in the Management of Refractory Immune Thrombocytopenia

Avani M. Singh, Filip Ionescu, Michael Jaglal, Bela Kis, Jennifer Eatrides

Blood (2022) 140 (Supplement 1): 11255–11256.

https://doi.org/10.1182/blood-2022-170400

Published: 2022

Journal Articles

Trends of Venous Thromboembolism Prophylaxis in Hospitalized Sickle Cell Patients

Filip Ionescu, Markie Sue Zimmer, Nwabundo Anusim, Marianne Terese Huben, Hycienth O Ahaneku, Michael Stender, Ishmael Jaiyesimi

Blood (2021) 138 (Supplement 1): 3088.

https://doi.org/10.1182/blood-2021-144719

Published: 2021

Journal Articles

Increasing Doses of Anticoagulation Are Associated with Improved Survival in Hospitalized COVID-19 Patients

Filip Ionescu, MD, Girish B Nair, MD MS, FACP, Ioana Petrescu, MD, Anish S Konde, MD, Markie Sue Zimmer, MD, Nwabundo Anusim, MBBS, Vishal Jindal, MD, Susanna Gaikazian, MD, Joseph Anderson, MD, Michael Stender, MD, Marianne Terese Huben, DO, Ishmael Jaiyesimi, DO, MS

Blood (2020) 136 (Supplement 1): 22.

https://doi.org/10.1182/blood-2020-134835

Published: 2020

Journal Articles

Inferior Vena Cava Filter Retrieval Trends: A Single Center Experience

Filip Ionescu, MD, Nwabundo Anusim, MD, Eva Ma, MD, Lihua Qu, MD MIS, Leann Blankenship, MD, Michael Stender, MD, Ishmael Jaiyesimi, DO, MS

Blood (2019) 134 (Supplement_1): 4690.

https://doi.org/10.1182/blood-2019-129366

Published: 2019

Journal Articles

Outcome of Morbidly Obese Patients with Acute Venous Thromboembolism Managed with Direct Oral Anticoagulants

Nwabundo Anusim, MD, Filip Ionescu, MD, Vishal Jindal, MD, Ruby Gupta, MD, Ishmael Jaiyesimi, DO, MS, Susanna Gaikazian, MD

Blood (2019) 134 (Supplement_1): 4973.

https://doi.org/10.1182/blood-2019-132202

Published: 2019

Journal Articles

Outcomes in Heparin-Induced Thrombocytopenia Managed with Direct Oral Anticoagulants

Nwabundo Anusim, MD, Filip Ionescu, MD, Anish S Konde, MD, Vishal Jindal, MD, Ruby Gupta, MD, Marianne Terese Huben, DO, Susanna Gaikazian, MD, Ishmael Jaiyesimi, DO, MS

Blood (2019) 134 (Supplement_1): 4975.

https://doi.org/10.1182/blood-2019-129485

Published: 2019

NARROW

Safety and Efficacy of Standard of Care (SOC) Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM), a Single Center Experience

Activity and Safety of Venetoclax (VEN)-Based Treatment in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (R/R MM)

Clinical Characteristics and Outcomes of Patients with MYD88 Positive Waldenström Macroglobulinemia: A Single Center Retrospective Analysis

Effect of Talquetamab on Responses in Patients with Relapsed and Refractory Multiple Myeloma with Prior Exposure to T-Cell Redirecting Therapies

Single Center Real World Experience of Talquetamab in Patients with Relapsed and Refractory Multiple Myeloma

Cladribine and Cyclophosphamide Lymphodepletion Prior to Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma

Cladribine and Cyclophosphamide Lymphodepletion Prior to Brexucabtagene Autoleucel in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia and Mantle Cell Lymphoma

Alternative Lymphodepletion Strategies Lead to Similar Response Rates and Toxicities in Standard-of-Care BCMA-Directed CAR-T Therapy in Relapsed Refractory Multiple Myeloma

Poor Hematopoietic Reserve at the Time of CD19 CAR T-Cell Infusion Is Associated with Long Term B-Cell Aplasia

Second-Line Chimeric Antigen Receptor T Cell Therapy (CAR-T) As Standard of Care for Relapsed-Refractory Large B-Cell Lymphoma (LBCL)

Fludarabine Lymphodepletion Exposure Is Associated with Idecabtagene Vicleucel Toxicity in Relapsed and Refractory Multiple Myeloma Patients: Real-World Experience from the US Myeloma Immunotherapy Consortium

Outcomes of Acute Myeloid Leukemia Relapsed Post-Allogeneic Hematopoietic Stem Cell Transplant Treated with Hypomethylating Agents and Venetoclax Combination: A Single Center Experience

Outpatient Treatment with Anti-Sars-Cov-2 Monoclonal Antibodies and Remdesivir for COVID19 Infections Demonstrates Encouraging Outcomes in Hematopoietic Stem Cell Transplant Recipients: A Single-Center Experience

Efficacy of Partial Splenic Embolization in the Management of Refractory Immune Thrombocytopenia

Trends of Venous Thromboembolism Prophylaxis in Hospitalized Sickle Cell Patients

Increasing Doses of Anticoagulation Are Associated with Improved Survival in Hospitalized COVID-19 Patients

Inferior Vena Cava Filter Retrieval Trends: A Single Center Experience

Outcome of Morbidly Obese Patients with Acute Venous Thromboembolism Managed with Direct Oral Anticoagulants

Outcomes in Heparin-Induced Thrombocytopenia Managed with Direct Oral Anticoagulants

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only